Endovascular Therapy for Renal Artery Stenosis in China
- Conditions
- Hypertension, RenovascularRenal Artery Obstruction
- Interventions
- Procedure: Endovascular Therapy
- Registration Number
- NCT03080519
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Brief Summary
A multicenter prospective registry planned to recruit more than 5 000 patients with renal artery stenosis was carried out in China. This primary purpose of this study was to evaluate the safety and efficacy of renal artery revascularization in the real world. The secondary purpose was to investigate the etiologic distribution of renal artery stenosis and optimize the indications for renal artery revascularization.
- Detailed Description
Currently,the endovascular therapy of renal artery stenosis (especially atherosclerotic) remains in dispute. Some randomized control trials published in recent years (including ASTRAL and CORAL trials) showed the lack of additional benefit for renal artery revascularization compared with sole medical therapy. However,these randomized control trials presented a number of limitations including low numbers of patients and non-stringent inclusion criteria. Given clinical medical practice entering the era of big data, the large-sample real-word studies would be more objective to answer some pending issues of randomized controlled trial.Therefore,a multicenter prospective registry planned to recruit more than 5 000 patients with renal artery stenosis was carried out. This primary purpose of this study was to evaluate the safety and efficacy of renal artery revascularization in the real world. The secondary purpose was to investigate the etiologic distribution of renal artery stenosis and optimize the indications for renal artery revascularization.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 5000
-
Age ≥ 14 at the time of informed consent
-
Diameter reduction of renal artery or main branch of renal artery≥ 60%,and ≥2 of four following conditions met:1)systolic hyperemic pressure gradient >20 mm Hg,2)captopril renoscitigraphy positive in the lesion side
,3)renin-angiotensin-aldosterone system significantly activated and 4)severe reduction (>25%) of glomendar filtration rate in the lesion side
-
office systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg while receiving 3 antihypertensive drugs,or office systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg without antihypertensive drugs
-
Serum creatinine level<264umol/L
-
Length of ipsilateral kidney ≥7.0 cm and glomendar filtration rate ≥10 ml／min
-
Urine protein <2+
- Unable to provide informed consent
- Unstable condition and unable to tolerate interventional therapy
- intolerance to antiplatelet drugs or contrast medium
- vascular anatomy not suitable for endovascular therapy
- Pregnant, nursing, or planning to be pregnant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Endovascular Therapy Endovascular Therapy Renal artery revascularization
- Primary Outcome Measures
Name Time Method Efficacy：Change in blood pressure compared to baseline Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months Safety: Change in estimated glomerular filtration rate compared to baseline Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- Secondary Outcome Measures
Name Time Method Device or procedure related acute adverse events (renal artery dissection,renal artery perforation,bleeding,and etc.) Perioperative period The incidence of major adverse event (cardiovascular or renal death,myocardial infarction,hospitalization for congestive heart failure, stroke, and renal failure) Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months The incidence of renal artery restenosis(>50%) Measured every 6 months from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Trial Locations
- Locations (16)
The Eighth Affiliated Hospital of Sun Yat-sen University
🇨🇳Shenzhen, Guangdong, China
Hongqi Hospital
🇨🇳Mudanjiang, Heilongjiang, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Xi'an NO.3 Hospital
🇨🇳Xi'an, Shanxi, China
Zhejiang Hospital
🇨🇳Hangzhou, Zhejiang, China
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
🇨🇳Beijing, Beijing, China
Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
Beijing Renhe Hospital
🇨🇳Beijing, Beijing, China
Lanzhou University Second Hospital
🇨🇳Lanzhou, Gansu, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Shanxi Cardiovascular Hospital
🇨🇳Taiyuan, Shanxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China
The General Hospital of Shenyang Military
🇨🇳Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shanxi, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China
Daping Hospital
🇨🇳Chongqing, Chongqing, China